|1.||Duncker, Dirk J G M: 1 article (03/2004)|
|2.||Laarman, GertJan: 1 article (03/2004)|
|3.||Tonino, Wilhelmus A L: 1 article (03/2004)|
|4.||Tavazzi, Luigi: 1 article (03/2004)|
|5.||van 't Hof, Arnoud W J: 1 article (03/2004)|
|6.||Guagliumi, Giulio: 1 article (03/2004)|
|7.||Simoons, Maarten L: 1 article (03/2004)|
|8.||Dirksen, Maurits T: 1 article (03/2004)|
|9.||PARI-MI Investigators (Protect Against Reperfusion Injury with ITF-1697 in acute Myocardial Infarction): 1 article (03/2004)|
|10.||Schönau, K: 1 article (01/2004)|
01/01/2004 - "Assessment of the safety and efficacy of the novel tetrapeptide ITF-1697 on infarct size after primary PTCA in acute myocardial infarction: a randomised, placebo-controlled pilot trial."
01/01/2004 - "The aim of this prospective, randomised, double-blind study in patients with acute myocardial infarction undergoing coronary revascularisation was to investigate the safety and efficacy of prolonged intravenous (i.v.) infusion of ITF-1697 at different doses on reduction of infarct size, as assessed by radionuclide imaging. "
03/01/2004 - "We performed a dose-finding study to assess safety, preliminary efficacy and clinical outcome of prolonged i.v. infusion of ITF-1697 in patients with an acute myocardial infarction (AMI) who were eligible for percutaneous coronary intervention (PCI). "
01/01/2004 - "The application of the tetrapeptide ITF-1697 during acute myocardial infarction to reduce infarct size was found to be feasible and safe in this pilot trial."
01/01/2004 - "Injection of technetium-99m (Tc99m) was followed by injection of ITF-1697 or placebo bolus and 24-hour infusion in patients with acute myocardial infarction. "